This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2019 Nov;74(5):713-715.

doi: 10.1053/j.ajkd.2019.03.432. Epub 2019 Jun 27.

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial

Mark E Cooper¹, Silvio E Inzucchi², Bernard Zinman³, Stefan Hantel⁴, Maximilian von Eynatten⁵, Christoph Wanner⁶, Audrey Koitka-Weber⁷

Affiliations

Affiliations

¹ Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia. Electronic address: mark.cooper@monash.edu.
² Section of Endocrinology, Yale School of Medicine, New Haven, CT.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
⁴ Boehringer Ingelheim International GmbH, Biberach.
⁵ Boehringer Ingelheim International GmbH, Ingelheim.
⁶ Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
⁷ Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; Boehringer Ingelheim International GmbH, Ingelheim; Department of Medicine, Würzburg University Clinic, Würzburg, Germany.

PMID: 31255334
DOI: 10.1053/j.ajkd.2019.03.432

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial

Mark E Cooper et al. Am J Kidney Dis. 2019 Nov.

. 2019 Nov;74(5):713-715.

doi: 10.1053/j.ajkd.2019.03.432. Epub 2019 Jun 27.

Authors

Mark E Cooper¹, Silvio E Inzucchi², Bernard Zinman³, Stefan Hantel⁴, Maximilian von Eynatten⁵, Christoph Wanner⁶, Audrey Koitka-Weber⁷

Affiliations

¹ Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia. Electronic address: mark.cooper@monash.edu.
² Section of Endocrinology, Yale School of Medicine, New Haven, CT.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
⁴ Boehringer Ingelheim International GmbH, Biberach.
⁵ Boehringer Ingelheim International GmbH, Ingelheim.
⁶ Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
⁷ Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; Boehringer Ingelheim International GmbH, Ingelheim; Department of Medicine, Würzburg University Clinic, Würzburg, Germany.

PMID: 31255334
DOI: 10.1053/j.ajkd.2019.03.432

No abstract available

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information